The National Academies Press

Currently Skimming:

Index
Pages 281-288

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.

From page 281... ... , 38, 43, 45, 52-54, 102, 104, 192-193, 229-231, 234-235, 244 Adjuvant therapy, for breast cancer, 11, 45-46 Adrenal insufficiency, 53, 55 AIDS, 105 Alzheimer's disease, 105 Amenorrhea, 4, 21 Animal models and studies, 15, 57-61, 262-266 abortifacient use, 58-59, 265-266 antiestrogenic effects, 247-249 breast cancer, 11, 43-44, 47, 60, 217-219 endometriosis therapy, 37-39 and labor induction, 8, 33, 34, 59-60 Antiandrogen effects, 235, 239, 240 Antiestrogenic effects, 9, 10, 153-154, 244-245, 247-249, 269-270 Read the entire page →
From page 282... ... 282 Antiglucocorticoid effects, 1, 13, 16, 52, 55, 76, 78, 104-105, 140-141, 234-239, 244 of cancer therapy, 10, 21, 40, 41, 236 of endometriosis therapy, 9, 38, 39 of low dosages, 4, 9, 21 research needs, 13, 55, 239-240 therapeutic, 13, 53-55, 170, 234-235, 239-240, 271 Antihormone antibodies, 73 Antitumor effects, 11, 43-44, 47, 103-104, 106, 217-219, 235-236 Apoptosis, and breast cancer therapy, 12, 43,103 Arthritis, 55, 236 Azastene, 258 B Biosynthesis inhibition, 73, 257-259 Bone retention and loss, 4, 10, 21, 22, 38, 40 Brain, see Meningiomas; Mood effects Breast cancer, 11, 41-47, 91, 103-104,105, 210, 271 animal studies, 11, 43-44, 47, 60, 217-219 dosages, 12, 46, 48 and oral contraceptives, 20 progesterone receptors, 11, 12, 42-43, 48, 123-124, 133, 213-217, 220-222 research needs, 11-12, 47-48, 222-224 and side effects, 12, 45 C Cancer and tumors, see Antitumor effects; Breast CLINICAL APPLICATIONS OF ANTIPROGESTINS cancer; Meningiomas; Uterine leiomyomas Cardiovascular effects, of prostaglandin, 27-28, 94, 167 Cataracts, 55, 236 Cervical mucus, 139-140,141 Cervical ripening, 7-8, 32-33, 96-97, 165, 270 for abortion, 32, 96-97, 175, 177-179, 270 dosages, 32, 177-178 side effects, 32 Cesarean section, 34 Chemoprevention, for breast cancer, 11, 45-46 China, abortifacient use and licensing, 149, 271 trials, 265 Cholesterol, 140 Chromatin modification, 88 Clinical trials, 2~3, 18 abortifacient use, 6, 7, 29, 31-32,165, 166-167,168-170, 176 breast cancer therapy, 11-12, 44-45, 47-48, 60, 103, 219-220, 223 cervical ripening, 177-179 contraceptive use, 4, 22, 160 endometriosis therapy, 10, 38-39,189, 190, 192-197 leiomyoma therapy, 10, 189-190, 198-207 meningioma therapy, 13, 49, 50 post-coital contraception, 5, 23, 160 Complications, see Antiglucocorticoid effects; Side effects and toxicity Conception, 19 Contraception, definition, 72, 98. See also Contraceptive use; Menses induction; Oral Read the entire page →
From page 283... ... , 7, 31, 187 Dimerization, 87, 122, 129-130 DNA binding, 87-88, 120-125 passim, 127, 129-130 Dosages, 140 abortifacient use, 2~27, 28, 31, 94, 166, 168-170, 185-186 breast cancer therapy, 12, 46, 48 cervical ripening, 32, 177-178 contraceptive use, 3, 4, 20-21, 141-142, 159 Cushing's syndrome, 54 Endometriosis therapy, 9 labor induction, 8, 33-34 leiomyoma therapy, 10, 40~1, 102 menses induction, 5 ovulation inhibition, 154-156 post-coital contraception, 22-23, 156-157 E Ectopic tissue, see Endometriosis Endometrial contraception, 100-101, 148, 157 Endometriosis, 8-9, 10, 3~39, 92, 102, 189, 190-197, 271 Endometrium, 3, 19, 21, 90-91, 150, 152-153 effects of contraceptive use, 4, 21, 22 End points, 140-141 Enzymatic inhibitors, 73, 257-259 Epidermal growth factor, 12, 48 Epostane, 73, 258-259 Estradiol, 9, 15, 22, 39, 73-74, 144 Estrogen, 14, 19, 139-140 and breast cancer, 42 and long-term use, 10, 144 Read the entire page →
From page 284... ... , 105, 237 Infertility, and endometriosis, 8, 9, 36, 37 Inflammation, 55, 236, 237 Insulin-like growth factor, 12, 48 Intrauterine devices, 98 Intraocular pressure, 54, 236 L Labor induction, 8, 33-34, 97, 179-180, 186-187 animal studies, 8, 33, 34, 59-60 cervical ripening for, 7, 32, 270 Lactation, 8, 33, 34, 139 Lamicel dilator, 97, 187 Laminaria tents, 31, 97, 175, 187 Leiomyomas, see Uterine leiomyomas Licensing, see Regulatory approval Ligand binding, 81-82, 84-85, 121, 122 Lilopristone, 16, 77, 78, 260 Read the entire page →
From page 285... ... INDEX Lipid profiles, 140 and contraceptive use, 4, 21, 22 Local administration, 54, 236, 238, 239 Long-term administration, 3-4, 18, 21, 105, 195~-197 side effects, 3, 18, 143-144, 196 Low-dosage administration, 4, 21, 22 Luteal phase, 6, 15, 19, 38, 140, 150, 152-153 and breast cancer, 42 contraceptive administration over, 3, 20-21, 99-100, 143, 148, 157-158 and menses induction, 5, 23 and post-coital administration, 156-158 Luteinizing hormone (LH) , 14, 40, 91, 102, 140, 141-142, 150 M Male contraception, 101-102 Mechanisms of action, 2, 18, 76-78 cervical ripening, 175, 177 myometrial gap junctions, 268 ovulation inhibition, 154-156 prostaglandin metabolism, 266-268 receptor mediation, 78-89, 120-130, 268-270 reproductive effects, 89-92, 141, 149-154, 164-165 research needs, 2, 18, 134-135, 144, 159-160 transcription activity, 75, 84, 88-89, 121-123, 127-128, 130-135 Meningiomas, 12-13, 48-50, 104 and side effects, 13, 21, 49 285 Menses induction, 5, 23-24, 98, 171 Menstrual cycle, 3, 19 contraceptive administration over, 3-4, 141-143 and endometriosis, 8 progesterone production, 3, =5, 19, 140 see also Follicular phase; Luteal phase; Menses induction Metabolism, 76-77, 237, 240 of prostaglandin, 266-268 Miscarriage, see Abortion; Fetal demise Misoprostol, 28, 30, 94, 95, 99, 100, 169-171 Mood effects of contraceptive use, 4, 21, 22 of progesterone, 140 Morning-after pill, 4, 22 Muscular deterioration, 54 Myocardial infarction, from abortifacient use, 27-28, 94 Myometrium, 31, 32, 40, 90, 139, 164, 268 Myopathy, 54 N Neonatal effects, 8 of labor induction, 33, 34, 97, 180 of unsuccessful abortion, 28, 167 New Drug Application, for abortifacient use, 6, 30 Norethisterone, 142 Novel antiprogestins, research needs, 106, 107 o Obesity, 105 Older women, and abortifacient use, 6, 28, 29, 167 Read the entire page →
From page 286... ... 286 Onapristone, 16, 78, 153, 260 breast cancer therapy, 42, 43, 44, 46 Oral contraceptives, 14, 20, 71, 187 in endometriosis therapy, 37 post-coital use, 4, 5, 22, 23, 156 side effects, 20, 156 Organon, 16-17, 260 Orosomucoid binding, 77, 26~265 Osteoporosis, 4, 10, 21, 22, 38, 40 Ovarian cysts, 4, 21, 3~37 Ovulation, 14, 58 Ovulation inhibition, 3, 16, 91, 148, 154-156 contraceptive application, 4, 21, 101, 142, 156-157 Oxytocin, 8, 34, 97, 179 p Pain and pain relief abortion, 94, 169, 170, 171 breast cancer therapy, 44 endometriosis therapy, 38, 102, 193 Phosphorylation, 123-124, 133 Pituitary gland, 14, 16 Placenta, progesterone production, 3, 19, 164 Post-coital contraception, =5 22-23, 98, 99, 143, 148, 157-158, 187 failure rates, 157-158 research needs, 160 side effects, 22~23, 156 Pregnancy, 1, 72 animal models, 58-60 progesterone role, 1, 3, 72, 139, 149, 164 see also Abortion; Cervical CLINICAL APPLICATIONS OF ANTIPROGESTINS ripening; Fetal demise; Labor induction Premenstrual syndrome, progesterone effects, 140 Progesterone, 1, ~5, 14, 16, 72, 254 and breast cancer, 42, 212-213 menstrual cycle production, 3, 4-5, 19, 140 and normal breast function, 211-212 ovarian production of, 3, 6, 15, 26 placental production, 3, 19, 164 pregnancy role, 1, 3, 72, 139, 149, 164 Progesterone receptors, 72, 254, 263-264 animal models, 57-58 of breast tumors, 11, 12, 4~43, 48, 123-124, 133, 213-217, 220-222 of leiomyomas, 9, 40 mechanisms of action, 81-89, 120-135, 149, 268, 269 membrane-bound, 134 of meningiomas, 12, 48-49 Programmed cell death, see Apoptosis Prostaglandin abortifacient use, 6, 7, 26-29, 31, 93-96, 165-171 passim, 175, 255, 258 and cervical ripening, 8, 32-33, 165 contraceptive use, 3, 158 and menses induction, 5, 24 metabolism, 266-268 side effects, 27-28, 94, 167, 175, 186 see also Gemeprost, Misoprostol, Sulprostone Read the entire page →
From page 287... ... INDEX Protocols, abortion, 27, 29-30, 166 Psychosis, 105 R Receptors, see Estrogen receptors; Progesterone receptors Regulatory approval, 6, 30 France, 2, 27, 93 Sweden, 2, 27 United Kingdom, 2, 27 Research Triangle Institute, 16-17, 245-246 Resistance to antiprogestins, of tumors, 12, 46, 220-222 Risk assessment, 4, 6, 29 Roussel-Uclaf, 16-17, 75-76, 149, 259 abortion protocol, 29-30, 166 S Saline injection, 7, 31 Schering AG, 16-17, 78 Septic shock, 105 Sexual behavior effects, 91 Side effects and toxicity abortifacient use, 27-28, 94, 167, 175, 186 breast cancer therapy, 12, 45 cervical ripening, 32 contraceptive use, 4, 21, 22 endometriosis therapy, 9, 10, 38, 191, 193-194, 196 leiomyoma therapy, 21, 40-41, 201 long-term use, 3, 18, 143-144, 196 meningioma therapy, 13, 21, 49 of oral contraceptives, 20, 156 287 post-coital contraception, 22-23, 156 of prostaglandin, 27-28, 94, 167, 175, 186 see also Antiglucocorticoid effects Smoking, and abortifacient use, 6, 28, 29, 167 Southwest Oncology Group, 13, 50 Special Programme of Research, Development and Research Training in Human Reproduction, 254-255, 257 Steroid-induced myopathy, 54 Sulprostone, 27, 28, 93-94, 166, 167 Surgical abortion, 6, 7, 31, 187 after mifepristone failure, 28, 94, 167 cervical ripening for, 175, 177-179 Sweden, abortifacient use and licensing, 2, 6- 27, 94, 149, 166 T Tamoxifen, 42, 44 45, 46, 7~75, 217-218, 223 Tenascin, 43 Teratogenicity, 28, 167 Testosterone, 37 Topical administration, 54, 236, 238, 239 Toxicity, see Antiglucocorticoid effects; Side effects and toxicity Transconformation, 85-86 Transcription activity, 75, 84, 88-89, 121-123, 127-128, 130-135 Transforming growth factor, 12, 48 Read the entire page →
From page 288... ... 288 Triphenylethylene derivatives, 73-74 Tumors, see Antitumor effects; Breast cancer; Meningiomas; Uterine leiomyomas U United Kingdom, abortifacient use and licensing, 2, 6, 27, 94, 149, 166 Uterine contractility, 164-165 Uterine leiomyomas, 9-10, 39~1, 92, 102-103, 189-190, 197-207, 271 dosages for, 10, 40-41, 102 research needs, 10 and side effects, 21, 40~41, 201 Uterine perforation, 7, 32 CLINICAL APPLICATIONS OF ANTIPROGESTINS V Viral disease, 54 W Wound healing, 55, 92, 105, 236, 270, 271 y Yuzpe regimen, 156 z ZK 98 299 antiprogest;in, 125, 130, 133, 219 ZK 112 993 antiprogestin, 43, 78 Read the entire page →

From page 281...

... , 38, 43, 45, 52-54, 102, 104, 192-193, 229-231, 234-235, 244 Adjuvant therapy, for breast cancer, 11, 45-46 Adrenal insufficiency, 53, 55 AIDS, 105 Alzheimer's disease, 105 Amenorrhea, 4, 21 Animal models and studies, 15, 57-61, 262-266 abortifacient use, 58-59, 265-266 antiestrogenic effects, 247-249 breast cancer, 11, 43-44, 47, 60, 217-219 endometriosis therapy, 37-39 and labor induction, 8, 33, 34, 59-60 Antiandrogen effects, 235, 239, 240 Antiestrogenic effects, 9, 10, 153-154, 244-245, 247-249, 269-270

Read the entire page →

From page 282...

... 282 Antiglucocorticoid effects, 1, 13, 16, 52, 55, 76, 78, 104-105, 140-141, 234-239, 244 of cancer therapy, 10, 21, 40, 41, 236 of endometriosis therapy, 9, 38, 39 of low dosages, 4, 9, 21 research needs, 13, 55, 239-240 therapeutic, 13, 53-55, 170, 234-235, 239-240, 271 Antihormone antibodies, 73 Antitumor effects, 11, 43-44, 47, 103-104, 106, 217-219, 235-236 Apoptosis, and breast cancer therapy, 12, 43,103 Arthritis, 55, 236 Azastene, 258 B Biosynthesis inhibition, 73, 257-259 Bone retention and loss, 4, 10, 21, 22, 38, 40 Brain, see Meningiomas; Mood effects Breast cancer, 11, 41-47, 91, 103-104,105, 210, 271 animal studies, 11, 43-44, 47, 60, 217-219 dosages, 12, 46, 48 and oral contraceptives, 20 progesterone receptors, 11, 12, 42-43, 48, 123-124, 133, 213-217, 220-222 research needs, 11-12, 47-48, 222-224 and side effects, 12, 45 C Cancer and tumors, see Antitumor effects; Breast CLINICAL APPLICATIONS OF ANTIPROGESTINS cancer; Meningiomas; Uterine leiomyomas Cardiovascular effects, of prostaglandin, 27-28, 94, 167 Cataracts, 55, 236 Cervical mucus, 139-140,141 Cervical ripening, 7-8, 32-33, 96-97, 165, 270 for abortion, 32, 96-97, 175, 177-179, 270 dosages, 32, 177-178 side effects, 32 Cesarean section, 34 Chemoprevention, for breast cancer, 11, 45-46 China, abortifacient use and licensing, 149, 271 trials, 265 Cholesterol, 140 Chromatin modification, 88 Clinical trials, 2~3, 18 abortifacient use, 6, 7, 29, 31-32,165, 166-167,168-170, 176 breast cancer therapy, 11-12, 44-45, 47-48, 60, 103, 219-220, 223 cervical ripening, 177-179 contraceptive use, 4, 22, 160 endometriosis therapy, 10, 38-39,189, 190, 192-197 leiomyoma therapy, 10, 189-190, 198-207 meningioma therapy, 13, 49, 50 post-coital contraception, 5, 23, 160 Complications, see Antiglucocorticoid effects; Side effects and toxicity Conception, 19 Contraception, definition, 72, 98. See also Contraceptive use; Menses induction; Oral

Read the entire page →

From page 283...

... , 7, 31, 187 Dimerization, 87, 122, 129-130 DNA binding, 87-88, 120-125 passim, 127, 129-130 Dosages, 140 abortifacient use, 2~27, 28, 31, 94, 166, 168-170, 185-186 breast cancer therapy, 12, 46, 48 cervical ripening, 32, 177-178 contraceptive use, 3, 4, 20-21, 141-142, 159 Cushing's syndrome, 54 Endometriosis therapy, 9 labor induction, 8, 33-34 leiomyoma therapy, 10, 40~1, 102 menses induction, 5 ovulation inhibition, 154-156 post-coital contraception, 22-23, 156-157 E Ectopic tissue, see Endometriosis Endometrial contraception, 100-101, 148, 157 Endometriosis, 8-9, 10, 3~39, 92, 102, 189, 190-197, 271 Endometrium, 3, 19, 21, 90-91, 150, 152-153 effects of contraceptive use, 4, 21, 22 End points, 140-141 Enzymatic inhibitors, 73, 257-259 Epidermal growth factor, 12, 48 Epostane, 73, 258-259 Estradiol, 9, 15, 22, 39, 73-74, 144 Estrogen, 14, 19, 139-140 and breast cancer, 42 and long-term use, 10, 144

Read the entire page →

From page 284...

... , 105, 237 Infertility, and endometriosis, 8, 9, 36, 37 Inflammation, 55, 236, 237 Insulin-like growth factor, 12, 48 Intrauterine devices, 98 Intraocular pressure, 54, 236 L Labor induction, 8, 33-34, 97, 179-180, 186-187 animal studies, 8, 33, 34, 59-60 cervical ripening for, 7, 32, 270 Lactation, 8, 33, 34, 139 Lamicel dilator, 97, 187 Laminaria tents, 31, 97, 175, 187 Leiomyomas, see Uterine leiomyomas Licensing, see Regulatory approval Ligand binding, 81-82, 84-85, 121, 122 Lilopristone, 16, 77, 78, 260

Read the entire page →

From page 285...

... INDEX Lipid profiles, 140 and contraceptive use, 4, 21, 22 Local administration, 54, 236, 238, 239 Long-term administration, 3-4, 18, 21, 105, 195~-197 side effects, 3, 18, 143-144, 196 Low-dosage administration, 4, 21, 22 Luteal phase, 6, 15, 19, 38, 140, 150, 152-153 and breast cancer, 42 contraceptive administration over, 3, 20-21, 99-100, 143, 148, 157-158 and menses induction, 5, 23 and post-coital administration, 156-158 Luteinizing hormone (LH) , 14, 40, 91, 102, 140, 141-142, 150 M Male contraception, 101-102 Mechanisms of action, 2, 18, 76-78 cervical ripening, 175, 177 myometrial gap junctions, 268 ovulation inhibition, 154-156 prostaglandin metabolism, 266-268 receptor mediation, 78-89, 120-130, 268-270 reproductive effects, 89-92, 141, 149-154, 164-165 research needs, 2, 18, 134-135, 144, 159-160 transcription activity, 75, 84, 88-89, 121-123, 127-128, 130-135 Meningiomas, 12-13, 48-50, 104 and side effects, 13, 21, 49 285 Menses induction, 5, 23-24, 98, 171 Menstrual cycle, 3, 19 contraceptive administration over, 3-4, 141-143 and endometriosis, 8 progesterone production, 3, =5, 19, 140 see also Follicular phase; Luteal phase; Menses induction Metabolism, 76-77, 237, 240 of prostaglandin, 266-268 Miscarriage, see Abortion; Fetal demise Misoprostol, 28, 30, 94, 95, 99, 100, 169-171 Mood effects of contraceptive use, 4, 21, 22 of progesterone, 140 Morning-after pill, 4, 22 Muscular deterioration, 54 Myocardial infarction, from abortifacient use, 27-28, 94 Myometrium, 31, 32, 40, 90, 139, 164, 268 Myopathy, 54 N Neonatal effects, 8 of labor induction, 33, 34, 97, 180 of unsuccessful abortion, 28, 167 New Drug Application, for abortifacient use, 6, 30 Norethisterone, 142 Novel antiprogestins, research needs, 106, 107 o Obesity, 105 Older women, and abortifacient use, 6, 28, 29, 167

Read the entire page →

From page 286...

... 286 Onapristone, 16, 78, 153, 260 breast cancer therapy, 42, 43, 44, 46 Oral contraceptives, 14, 20, 71, 187 in endometriosis therapy, 37 post-coital use, 4, 5, 22, 23, 156 side effects, 20, 156 Organon, 16-17, 260 Orosomucoid binding, 77, 26~265 Osteoporosis, 4, 10, 21, 22, 38, 40 Ovarian cysts, 4, 21, 3~37 Ovulation, 14, 58 Ovulation inhibition, 3, 16, 91, 148, 154-156 contraceptive application, 4, 21, 101, 142, 156-157 Oxytocin, 8, 34, 97, 179 p Pain and pain relief abortion, 94, 169, 170, 171 breast cancer therapy, 44 endometriosis therapy, 38, 102, 193 Phosphorylation, 123-124, 133 Pituitary gland, 14, 16 Placenta, progesterone production, 3, 19, 164 Post-coital contraception, =5 22-23, 98, 99, 143, 148, 157-158, 187 failure rates, 157-158 research needs, 160 side effects, 22~23, 156 Pregnancy, 1, 72 animal models, 58-60 progesterone role, 1, 3, 72, 139, 149, 164 see also Abortion; Cervical CLINICAL APPLICATIONS OF ANTIPROGESTINS ripening; Fetal demise; Labor induction Premenstrual syndrome, progesterone effects, 140 Progesterone, 1, ~5, 14, 16, 72, 254 and breast cancer, 42, 212-213 menstrual cycle production, 3, 4-5, 19, 140 and normal breast function, 211-212 ovarian production of, 3, 6, 15, 26 placental production, 3, 19, 164 pregnancy role, 1, 3, 72, 139, 149, 164 Progesterone receptors, 72, 254, 263-264 animal models, 57-58 of breast tumors, 11, 12, 4~43, 48, 123-124, 133, 213-217, 220-222 of leiomyomas, 9, 40 mechanisms of action, 81-89, 120-135, 149, 268, 269 membrane-bound, 134 of meningiomas, 12, 48-49 Programmed cell death, see Apoptosis Prostaglandin abortifacient use, 6, 7, 26-29, 31, 93-96, 165-171 passim, 175, 255, 258 and cervical ripening, 8, 32-33, 165 contraceptive use, 3, 158 and menses induction, 5, 24 metabolism, 266-268 side effects, 27-28, 94, 167, 175, 186 see also Gemeprost, Misoprostol, Sulprostone

Read the entire page →

From page 287...

... INDEX Protocols, abortion, 27, 29-30, 166 Psychosis, 105 R Receptors, see Estrogen receptors; Progesterone receptors Regulatory approval, 6, 30 France, 2, 27, 93 Sweden, 2, 27 United Kingdom, 2, 27 Research Triangle Institute, 16-17, 245-246 Resistance to antiprogestins, of tumors, 12, 46, 220-222 Risk assessment, 4, 6, 29 Roussel-Uclaf, 16-17, 75-76, 149, 259 abortion protocol, 29-30, 166 S Saline injection, 7, 31 Schering AG, 16-17, 78 Septic shock, 105 Sexual behavior effects, 91 Side effects and toxicity abortifacient use, 27-28, 94, 167, 175, 186 breast cancer therapy, 12, 45 cervical ripening, 32 contraceptive use, 4, 21, 22 endometriosis therapy, 9, 10, 38, 191, 193-194, 196 leiomyoma therapy, 21, 40-41, 201 long-term use, 3, 18, 143-144, 196 meningioma therapy, 13, 21, 49 of oral contraceptives, 20, 156 287 post-coital contraception, 22-23, 156 of prostaglandin, 27-28, 94, 167, 175, 186 see also Antiglucocorticoid effects Smoking, and abortifacient use, 6, 28, 29, 167 Southwest Oncology Group, 13, 50 Special Programme of Research, Development and Research Training in Human Reproduction, 254-255, 257 Steroid-induced myopathy, 54 Sulprostone, 27, 28, 93-94, 166, 167 Surgical abortion, 6, 7, 31, 187 after mifepristone failure, 28, 94, 167 cervical ripening for, 175, 177-179 Sweden, abortifacient use and licensing, 2, 6- 27, 94, 149, 166 T Tamoxifen, 42, 44 45, 46, 7~75, 217-218, 223 Tenascin, 43 Teratogenicity, 28, 167 Testosterone, 37 Topical administration, 54, 236, 238, 239 Toxicity, see Antiglucocorticoid effects; Side effects and toxicity Transconformation, 85-86 Transcription activity, 75, 84, 88-89, 121-123, 127-128, 130-135 Transforming growth factor, 12, 48

Read the entire page →

From page 288...

... 288 Triphenylethylene derivatives, 73-74 Tumors, see Antitumor effects; Breast cancer; Meningiomas; Uterine leiomyomas U United Kingdom, abortifacient use and licensing, 2, 6, 27, 94, 149, 166 Uterine contractility, 164-165 Uterine leiomyomas, 9-10, 39~1, 92, 102-103, 189-190, 197-207, 271 dosages for, 10, 40-41, 102 research needs, 10 and side effects, 21, 40~41, 201 Uterine perforation, 7, 32 CLINICAL APPLICATIONS OF ANTIPROGESTINS V Viral disease, 54 W Wound healing, 55, 92, 105, 236, 270, 271 y Yuzpe regimen, 156 z ZK 98 299 antiprogest;in, 125, 130, 133, 219 ZK 112 993 antiprogestin, 43, 78

Read the entire page →

← Previous Chapter Skim

This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.

Index Pages 281-288

Index
Pages 281-288